Preclinical Science Regarding Cannabinoids as Analgesics: An Overview
Open accessThe DOI matches its Crossref record; 74 of the 76 references it cites were found in a registry or an index.
Abstract
Modern pharmacology of cannabinoids began in 1964 with the isolation and partial synthesis of delta‐9‐tetrahydrocannabinol, the main psychoactive agent in herbal cannabis. Since then, potent antinociceptive and antihyperalgesic effects of cannabinoid agonists in animal models of acute and chronic pain; the presence of cannabinoid receptors in pain‐processing areas of the brain, spinal cord and periphery; and evidence supporting endogenous modulation of pain systems by cannabinoids has provided support that cannabinoids exhibit significant potential as analgesics. The present article presents an overview of the preclinical science.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures























Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633 · cited 1×
“Endocannabinoids Until the end of the 20th century, only two major endocannabinoids, anandamide (N-arachidonoyl-ethanolamine [AEA]) and 2-arachidonylglycerol (2-AG) had been discovered (25-27).”
BackgroundMolecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“Three years later, a second cannabinoid receptor (CB2) was discovered and cloned (10).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“Within a short time, the cannabinoid receptor (now called CB1) was discovered and cloned from rat and human brain (9).”
BackgroundMechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“Endocannabinoids Until the end of the 20th century, only two major endocannabinoids, anandamide (N-arachidonoyl-ethanolamine [AEA]) and 2-arachidonylglycerol (2-AG) had been discovered (25-27).”
BackgroundDetermination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 2×
“Furthermore, dynorphin A (1-8) antiserum and antisense to the kappa-1 receptor antagonized the effect (2,3).”
BackgroundIsolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393 · cited 2×
“Modern pharmacology of cannabinoids began in 1964 when the major psychoactive constituent of cannabis, delta-9tetrahydrocannabinol (∆-9-THC), was isolated in pure form, its structure elucidated and later synthesized (1).”
Background2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 3×
“amygdala (emotional response and fear), the brainstem (arousal) and the nucleus of the solitary tract (nausea and vomiting) (2,12,15-21) (Figure 2).”
BackgroundMethodPharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470 · cited 1×
“amygdala (emotional response and fear), the brainstem (arousal) and the nucleus of the solitary tract (nausea and vomiting) (2,12,15-21) (Figure 2).”
BackgroundBisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Endocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260 · cited 1×
“Endocannabinoid signalling in the brain In contrast to classical neurotransmitters, investigators have identified that endocannabinoids are able to function as retrograde synaptic messengers (36).”
BackgroundThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Control of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056 · cited 6×
“Intrathecal injection of (methyl-6-phenylethynyl) pyridine, a selective metabotropic glutamate-5 receptor antagonist, reversed the antihyperalgesic effect of intrathecal WIN55,212-2 in a rat loose ligation sciatic nerve model (50).”
BackgroundInfluentialHuang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T. J., Krey, J. F., Chu, C. J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122196999 · Cited by 964
The effects of cannabinoids on the brain
Ameri, A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00087-2 · Cited by 812
Cannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Mailleux, P., & Vanderhaeghen, J.-J. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90409-u · Cited by 664 · cited 1×
“The distribution of cannabinoid receptors has been examined by several methods (12-14).”
MethodPorter, A. C., Sauer, J.-M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J., Nomikos, G. G., Carter, P., Bymaster, F. P., Leese, A. B., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1020 · Cited by 615 · cited 3×
“AEA, NADA and noladin are more selective for CB1, virodhamine appears to prefer CB2 and 2-AG is equipotent for both CB1 and CB2 (28).”
BackgroundCannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
Richardson, J. D., Kilo, S., & Hargreaves, K. M. (1998) · Pain · doi:10.1016/s0304-3959(97)00213-3 · Cited by 500 · cited 4×
“Peripheral administration of AEA attenuates hyperalgesia and edema via a CB1 receptor mechanism and inhibits capsaicin-evoked plasma extravasation into the hindpaw (51).”
BackgroundInfluentialPharmacology of Cannabinoid Receptors
Howlett, A. C. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.003135 · Cited by 488 · cited 1×
“effect of morphine but not of THC and its analogues (35).”
BackgroundPain modulation by release of the endogenous cannabinoid anandamide
Walker, J. M., Huang, S. M., Strangman, N. M., Tsou, K., & Sañudo-Peña, M. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12198 · Cited by 485 · cited 4×
“Supraspinally, in the PAG, it has been demonstrated that administration of cannabinoid antagonists produces hyperalgesia and blocks the analgesia produced by electrical stimulation of the dorsal PAG (47,55).”
MethodInfluentialThe endocannabinoid system: a general view and latest additions
Petrocellis, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 475
The endogenous cannabinoid system protects against colonic inflammation
Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B. F., Ferri, G.-L., Sibaev, A., Storr, M., & Lutz, B. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19465 · Cited by 460 · cited 1×
“This work supports evidence that CB1 receptors mediate intrinsic protective signals that counteract proinflammatory responses and indicates the endocannabinoid system is a promising target for the treatment of gastrointestinal disorders with excessive inflammatory responses (79).”
BackgroundAn analgesia circuit activated by cannabinoids
Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L. (1998) · Nature · doi:10.1038/26481 · Cited by 411 · cited 1×
“Furthermore, microinfusion with the cannabinoid agonist WIN55,212-2 directly into the RVM in rats leads to increased ‘off-cell’ activity with increased tail-flick latencies, indicating that cannabinoids act directly within the RVM to affect off-cell activity (41).”
BackgroundCB2 cannabinoid receptor-mediated peripheral antinociception
Malan, P. T., Ibrahim, M. M., Deng, H., Liu, Q., Mata, H. P., Vanderah, T., Porreca, F., & Makriyannis, A. (2001) · Pain · doi:10.1016/s0304-3959(01)00321-9 · Cited by 391
The endogenous cannabinoid system protects against colonic inflammation
Massa, F., Marsicano, G., Hermann, H., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419465 · Cited by 387
BISOGNO, T., MELCK, D., BOBROV, M. Y., GRETSKAYA, N. M., BEZUGLOV, V. V., De PETROCELLIS, L., & Di MARZO, V. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510817 · Cited by 381 · cited 4×
“AEA, NADA and noladin are more selective for CB1, virodhamine appears to prefer CB2 and 2-AG is equipotent for both CB1 and CB2 (28).”
BackgroundInfluentialTopical and Peripherally Acting Analgesics
Sawynok, J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.1 · Cited by 344
Herzberg, U., Eliav, E., Bennett, G. J., & Kopin, I. J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13308-5 · Cited by 307 · cited 1×
“In models of chronic pain, cannabinoids exhibit greater potency and efficacy in both inflammatory (60) and neuropathic pain (61).”
BackgroundSynergistic interactions between cannabinoid and opioid analgesics
Cichewicz, D. L. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.038 · Cited by 305 · cited 5×
“CB1 and mu opioid roles in the synergy (57).”
BackgroundInfluentialAntihyperalgesic effects of spinal cannabinoids
Richardson, J. D., Aanonsen, L., & Hargreaves, K. M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01621-x · Cited by 275 · cited 2×
“Spinal sites of action Several investigators have demonstrated that cannabinoids also inhibit pain by a direct spinal action (16,43-49).”
BackgroundSpinal and supraspinal components of cannabinoid-induced antinociception.
Lichtman, A. H., & Martin, B. R. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20242-7 · Cited by 217 · cited 1×
“Spinal sites of action Several investigators have demonstrated that cannabinoids also inhibit pain by a direct spinal action (16,43-49).”
BackgroundThe Cannabinoid System and Cytokine Network
Klein, T. W., Lane, B., Newton, C. A., & Friedman, H. (2000) · Proceedings of the Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.2000.22501.x · Cited by 214 · cited 1×
“In addition, cannabinoids attenuate nitric oxide production from stimulated macrophages via a CB2 receptor-mediated action (7), and have also been demonstrated to have profound and complex effects on cytokine production (73).”
BackgroundWelch, S. P., & Stevens, D. L. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10720-9 · Cited by 206 · cited 1×
“Spinal sites of action Several investigators have demonstrated that cannabinoids also inhibit pain by a direct spinal action (16,43-49).”
BackgroundLim, G., Sung, B., Ji, R.-R., & Mao, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00242-2 · Cited by 195
Cannabinoid receptors undergo axonal flow in sensory nerves
Hohmann, A. G., & Herkenham, M. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00220-1 · Cited by 194 · cited 2×
“amygdala (emotional response and fear), the brainstem (arousal) and the nucleus of the solitary tract (nausea and vomiting) (2,12,15-21) (Figure 2).”
BackgroundConti, S., Costa, B., Colleoni, M., Parolaro, D., & Giagnoni, G. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704466 · Cited by 190
Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord
Hohmann, A. G., Briley, E. M., & Herkenham, M. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01321-3 · Cited by 183 · cited 4×
“In addition, both systemic and intracerebroventricular administration of cannabinoids have been shown to decrease noxious heat-evoked activity of wide dynamic range (WDR) neurons in a manner sensitive to spinalization, indicating a supraspinal site of action and descending modulation of WDR neurons (17).”
BackgroundInfluentialEndocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy
Rice, A. S. C., Farquhar-Smith, W. P., & Nagy, I. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0362 · Cited by 183 · cited 15×
“Pain Res Manage Vol 10 Suppl A Autumn 2005 9A Agent Action Comments Naturally occurring cannabinoids ∆-9-THC CB1 and CB2 agonist Main psychoactive constituent of cannabis Cannabidiol Unknown mode of action Nonpsychoactive constituent of cannabis Endogenous cannabinoids Anandamide CB1 partial agonist Also binds to TRPV…”
BackgroundInfluentialHypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia
Richardson, J. D., Aanonsen, L., & Hargreaves, K. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00451.1998 · Cited by 182 · cited 3×
“Spinally, it has been demonstrated that hypoactivity of the spinal cannabinoid system has been associated with N-methylD-aspartate-dependent hyperalgesia (49).”
BackgroundMartin, W. J., Hohmann, A. G., & Walker, J. M. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-20-06601.1996 · Cited by 172
An examination of the central sites of action of cannabinoid-induced antinociception in the rat
Martin, W. J., Patrick, S. L., Coffin, P. O., Tsou, K., & Walker, J. M. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00195-c · Cited by 165
Martin, W. J., Coffin, P. O., Attias, E., Balinsky, M., Tsou, K., & Walker, J. M. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01368-7 · Cited by 164
Endogenous cannabinoids as an aversive or counter-rewarding system in the rat
Sañudo-Peña, M. C., Tsou, K., Delay, E. R., Hohman, A. G., Force, M., & Walker, J. M. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13424-3 · Cited by 163 · cited 1×
“amygdala (emotional response and fear), the brainstem (arousal) and the nucleus of the solitary tract (nausea and vomiting) (2,12,15-21) (Figure 2).”
BackgroundSR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
Richardson, J. D., Aanonsen, L., & Hargreaves, K. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00952-1 · Cited by 149
Differences in G-protein activation by μ- and δ-opioid, and cannabinoid, receptors in rat striatum
Sim, L. J., Selley, D. E., Xiao, R., & Childers, S. R. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00211-7 · Cited by 147
Martin, W. J., Tsou, K., & Walker, J. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00044-5 · Cited by 138 · cited 1×
“Direct brain injections into areas involved in descending inhibition of spinal nociceptive neurons elicits antinociceptive effects; these areas include the PAG in the midbrain, the RVM and the noradrenergic nucleus A5 in the medulla (38-40).”
BackgroundSumariwalla, P. F., Gallily, R., Tchilibon, S., Fride, E., Mechoulam, R., & Feldmann, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20050 · Cited by 134 · cited 2×
“however, it binds to CB1 receptors and has been found to cause sedation in mice (70).”
BackgroundHohmann, A. G., Farthing, J. N., Zvonok, A. M., & Makriyannis, A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060079 · Cited by 133 · cited 1×
“These data provide evidence that actions at CB2 receptors are sufficient to normalize nociceptive thresholds and produce antinociception in persistent pain states (74).”
BackgroundInteractions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Smith, P. B., Welch, S. P., & Martin, B. R. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38633-7 · Cited by 131
Hohmann, A. G., Martin, W. J., Tsou, K., & Walker, J. M. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00196-d · Cited by 120
Cannabinoid Transmission and Pain Perception
Martin, B. R., & Lichtman, A. H. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0218 · Cited by 117 · cited 3×
“Taken together, these data support a role for the spinal noradrenergic system in cannabinoid-induced antinociception (3).”
BackgroundLever, I. J., & Rice, A. S. C. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_10 · Cited by 115
Hohmann, A. G., & Herkenham, M. A. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00534-5 · Cited by 115 · cited 1×
“These experiments include suppression of neurophysiological responses to all types of nociceptive stimuli tested, suppression of windup (a model of central sensitization observed in chronic pain) and suppression of increased spontaneous firing following injection of the inflammatory agent complete Freund’s adjuvant (2…”
BackgroundCannabinoid-induced antinociception is mediated by a spinalα2-noradrenergic mechanism
Lichtman, A. H., & Martin, B. R. (1991) · Brain Research · doi:10.1016/0006-8993(91)90017-p · Cited by 114
Hohmann, A. G., Tsou, K., & Walker, J. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00802-7 · Cited by 112
Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
Strangman, N. M., Patrick, S. L., Hohmann, A. G., Tsou, K., & Walker, J. M. (1998) · Brain Research · doi:10.1016/s0006-8993(98)01031-2 · Cited by 109 · cited 4×
“Supraspinally, in the PAG, it has been demonstrated that administration of cannabinoid antagonists produces hyperalgesia and blocks the analgesia produced by electrical stimulation of the dorsal PAG (47,55).”
BackgroundInfluentialCannabinoids modulate pain by multiple mechanisms of action
Richardson, J. D. (2000) · The Journal of Pain · doi:10.1016/s1526-5900(00)90082-8 · Cited by 109 · cited 9×
“These are the ‘classical’ cannabinoid ∆-9-THC, the ‘nonclassical’ cannabinoid CP55,940, the aminoalkylindole WIN55,212-2, the ‘eicosanoid’ cannabinoid AEA, and additional fatty acid ethanolamides and esters that act as endocannabinoids (2,4).”
BackgroundInfluentialYAKSH, T. L. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02612.x · Cited by 103 · cited 1×
“Spinal sites of action Several investigators have demonstrated that cannabinoids also inhibit pain by a direct spinal action (16,43-49).”
BackgroundInvolvement of cannabinoid receptors in gut motility and visceral perception
Hornby, P. J., & Prouty, S. M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705783 · Cited by 103 · cited 2×
“The upper gastrointestinal tract is strongly influenced by CB1 receptor activation on central vagal pathways, whereas intestinal peristalsis can be modified by CB1 receptor activation in the absence of extrinsic input (78).”
BackgroundBurstein, S. H., Audette, C. A., Breuer, A., Devane, W. A., Colodner, S., Doyle, S. A., & Mechoulam, R. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00095a007 · Cited by 99 · cited 1×
“cannabinoids without psychotropic activity (68-70).”
Possible involvement of the endocannabinoid system in the actions of three clinically used drugs
Fowler, C. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.12.001 · Cited by 96 · cited 1×
“Old antiinflammatory analgesic drugs such as indomethacin and flurbiprofen activate CB1 receptors via a decrease in FAAH degradation and, therefore, an increase in AEA concentration, suggesting the potential for a cannabinoid mechanism of action contributing to their effects (77).”
BackgroundTopical cannabinoid enhances topical morphine antinociception
Yesilyurt, O., Dogrul, A., Gul, H., Seyrek, M., Kusmez, O., Ozkan, Y., & Yildiz, O. (2003) · Pain · doi:10.1016/s0304-3959(03)00245-8 · Cited by 96 · cited 1×
“Furthermore, it has been demonstrated that topical application of cannabinoid agonist (WIN55,212-2) enhances the antinociceptive effect of topical morphine via a CB1-mediated effect; in addition, spinally ineffective doses of WIN55,212-2 potentiate the antinociceptive effects of topical morphine (54).”
BackgroundThe Selective Cannabinoid Antagonist SR 141716A Blocks Cannabinoid-Induced Antinociception in Rats
Lichtman, A. H., & Martin, B. R. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00121-9 · Cited by 93
Cannabinoids and the Immune System
Klein, T., Newton, C. A., & Friedman, H. P. (2001) · Pain Research and Management · doi:10.1155/2001/326867 · Cited by 91 · cited 2×
“Since that time, studies have demonstrated the presence of CB2 receptors throughout the immune system (22,23).”
BackgroundCosta, B., Colleoni, M., Conti, S., Trovato, A. E., Bianchi, M., Sotgiu, M. L., & Giagnoni, G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705587 · Cited by 89 · cited 1×
“Furthermore, repeated administration of WIN55,212-2 given subcutaneously reversed the development of hyperalgesia that normally develops in chronic constriction of the sciatic nerve in rats (67), supporting that cannabinoids may play a role in prevention of neuropathic pain if given early after nerve injury.”
BackgroundCB1 cannabinoid receptor-G protein association: a possible mechanism for differential signaling
Mukhopadhyay, S., Shim, J., Assi, A.-A. A., Norford, D. C., & Howlett, A. C. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00153-6 · Cited by 87 · cited 1×
“The endocannabinoids vary in their activity at the receptor depending on the type of intracellular event measured (32).”
BackgroundStrangman, N. M., & Walker, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.1.472 · Cited by 81
Topical cannabinoid antinociception: synergy with spinal sites
Dogrul, A., Gul, H., Akar, A., Yildiz, O., Bilgin, F., & Guzeldemir, E. (2003) · Pain · doi:10.1016/s0304-3959(03)00068-x · Cited by 78 · cited 1×
“A number of studies have demonstrated a peripheral antinociceptive action for cannabinoid agonists in preclinical models (50-53); both CB1 (51,53) and CB2 receptor agonists (52) exhibit peripheral antinociceptive action.”
BackgroundWenger, Fernández‐Ruiz, & Ramos (1999) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1999.00402.x · Cited by 77
Meng, I. D., & Johansen, J. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.10.001 · Cited by 66 · cited 1×
“The use of an opioid is not required for the cannabinoid to produce this effect (42).”
BackgroundWalker, J. M., Strangman, N. M., & Huang, S. M. (2001) · Pain Research and Management · doi:10.1155/2001/413641 · Cited by 47
Pharmacology of Cannabinoid Receptors
Howlett, A. C. (1995) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.35.1.607 · Cited by 28
Valani, R. (2022) · Springer eBooks · doi:10.1007/978-3-031-12722-9_3 · Cited by 12
Research works printed but not linked: 5
- [14]14. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical localization of cannabinoid CB1 receptors in rat central nervous system. Neuroscience 1998;83:393-411.
- [15]15. Herkenham M. Localization of cannabinoid receptors in brain and periphery. In: Pertwee RG, ed. Cannabinoid Receptors. New York: Academic Press 1995:145-66.
- [24]24. Gong JP, Onaivi E, Uhl G. Cannabinoid CB2 receptors: Immunhistochemical localization in rat brain. ICRS abstracts. 15th Annual Symposium on the Cannabinoids, Clearwater, Florida, June 24-27, 2005.
- [37]37. Martin WJ, Lai NK, Patrick SL, Tsou K, Walker JM. Antinociceptive actions of WIN 55,212-2 following intraventricular administration in rats. Brain Res 1993;629:300-4.
- [60]60. Tsou K, Lowitz KA, Hohmann AG, et al. Suppression of noxious stimulus-evoked expression of fos-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 1995;70:791-8.
Cited by
Endocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
Fraser, G. A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00071.x · Cited by 283
“The CB2 is mostly distributed peripherally [13,14].”
BackgroundThe Pharmacotherapy of Chronic Pain: A Review
Lynch, M. E., & Watson, C. P. N. (2006) · Pain Research and Management · doi:10.1155/2006/642568 · Cited by 164
Self-citationNeuromodulators for pain management in rheumatoid arthritis
Richards, B. L., Whittle, S. L., & Buchbinder, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008921.pub2 · Cited by 100
A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting
Ware, M. A., Daeninck, P., & Maida, V. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1132 · Cited by 107
“…release, a process known as depolarization-induced suppression of inhibition (DSI) (Freund et al 2003; Diana and Mart 2004) Several neurotransmitters mediate nausea and vomiting, including serotonin, dopamine, GABA, glutamate, cannabinoids, and others (Andrews et al 1998; Lynch 2005).”
Metadata
- Authors
- Lynch, M.
- Affiliations
- Dalhousie University (CA)
- Corresponding author
- Lynch, ME
- Venue
- Pain Research and Management
- Publisher
- Wiley
- Published
- 2005-01
- Volume
- 10
- Issue
- A
- Pages
- 7A-14A
- ISSN
- 1203-6765 (ISSN-L)
- 1918-1523
- OpenAlex
- W2346786802
- Cited by
- 20
- References
- 76
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2018: 1 · 2012: 1
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pain Research and Management (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- cannabinoids, analgesics, delta-9-tetrahydrocannabinol, cannabinoid receptors, antinociception, antihyperalgesia, chronic pain, acute pain, endocannabinoid system, pain processing, animal models of pain
- MeSH terms
- Analgesics, Animals, Brain, Cannabinoids, Pain, Receptors, Cannabinoid, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.